NVO - Novo Nordisk says prices dropping for Wegovy Ozempic: report
2024-05-02 09:17:44 ET
More on Novo Nordisk
- Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
- Novo Nordisk Remains The Better Buy After A Moderate Pullback
- Novo Nordisk: The Moat Won't Last Forever
- Novo Nordisk lifts guidance as Ozempic, Wegovy sales surge; but stock falls 3%
- Novo Nordisk GAAP EPADR of DKK 5.68, revenue of DKK 65.35B; updates FY24 outlook